| Protocol ID |
|
Title |
|
| In-House-GVHD |
|
Assessment of Regulatory T Cells Prior to and Following Autologous Stem Cell Transplant for Multiple Myeloma
Keywords: Autologous Stem Cell Transplant for Multiple Myeloma |
|
| RDCRN 6501 |
|
Longitudinal Study of Immune Mediated Disorders after Allogeneic Hemotopoietic Cell Transplantation
Keywords: Allogeneic Hemotopoietic Cell Transplantation |
|
| In-House-GVHD |
|
Acquisitions of Graft v. Host Disease Sample in Pre-Clinical Studies
Keywords: Graft v. Host Disease |
|
| C10403 |
|
An Intergroup Phase II Clinical Trial of Adolecents and Young Adults with Untreated Acute Lymphoblastic Leukemia
Keywords: Adolecents and Young Adults with Untreated Acute Lymphoblastic Leukemia |
|
| In-House |
|
Laboratory Studies of Iron Metabolism in Blood Cells from Patients with Hematochromatosis
Keywords: patients with hematochromatosis |
|
In-House: Pre-Clinical
Vaccine for MM |
|
Pre-Clinical Studies on Vaccine Derived From Patient-Derived Myeloma Cells
Keywords: Multiple Myeloma |
|
| In-House: Haplo-Cord |
|
Phase II Study: Myeloablative Human Stem Cell Transplant (HSCT) Using Selected Mismatched Related Donor and One Umbilical Cord Unit
Keywords: Human Stem Cell Transplant |
|
| E2903 |
|
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
Keywords: Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia |
|
| KP- 339 |
|
A Phase III Randomized Study to Assess the Efficacy and Safety or Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
Keywords: Multiple Myeloma Patients Previously Treated with Bortezomib |
|
| CTN 0701 |
|
PhaseII Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response
Keywords: Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response |
|
| E1906 |
|
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia
Keywords: Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia |
|
| E2905 |
|
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid ®) Alone in Combination with Epoetin Alfa (Procrit ®) in Subjects with Low- or Intermediate -1 Risk MDS and Symptomatic Anemia
Keywords: Low- or Intermediate -1 Risk MDS and Symptomatic Anemia |
|
| C-AML |
|
Randomized Phase III Study of Elacytarabine vs. Investigators Choice in Patients with Late Stage Acute Myeloid Leukemia
Keywords: Late Stage Acute Myeloid Leukemia |
|
| AT7519M/0004 |
|
A Phase I/II Open-Label Multicenter Study of AT7519M Alone and in Combination with Bortezomib in Patients with Previously Treated Multiple Myeloma
Keywords: Patients with Previously Treated Multiple Myeloma |
|
| CTN 0702 |
|
A Trial of Single Autologous Transplant with or without Consolidation Therapy vs. Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Keywords: Patients with Multiple Myeloma |
|
| WON HO10407 |
|
A Phase II Study of Bortezomib and Temsirolimus for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Keywords: Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
|
| CIBMTR RDSafe |
|
A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Keywords: Hematopoietic Stem Cell Donor Safety and Quality of Life |
|
| CTN 0901 |
|
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intesnsity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Keywords: Myelodysplastic Syndrome or Acute Myeloid Leukemia |
|
| E2906 |
|
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age >60 Years)
Keywords: Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age >60 Years) |
|
| C05013 |
|
An Open-Label, Randomized, Phase II Study to Assess the Effectiveness of RCHOP with or without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
Keywords: Diffuse Large B-Cell Lymphoma |
|
| FH- 2431.00 |
|
Long-Term Outcomes of Participants in Clinical Studies of Immune-Mediated Disorder
Keywords: Immune-Mediated Disorder |
|
| In-house |
|
Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Keywords: Refractory Acute Graft Versus Host Disease |
|
| E2408 |
|
A 3 Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide/ Rituximab in High Risk Follicular Lymphoma
Keywords: High Risk Follicular Lymphoma |
|
| Industry-Multiple Myeloma |
|
Phase I/II, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/ Refractory Multiple Myeloma
Keywords: Relapsed or Relapsed/ Refractory Multiple Myeloma |
|
| FH-2230.00 |
|
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation
Keywords: Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation |
|
| FH-2448.00 |
|
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Trial
Keywords: Donor Hematopoietic Cell Transplantation |
|
| S0805 |
|
Phase II Study of Combination fo Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Keywords: Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) |
|
| S0535 |
|
A Phase II Study of ATRA, Aresenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia
Keywords: Previously Untreated High-Risk Acute Promyelocytic Leukemia |
|
| S1106 |
|
A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients <65 years of Age with Previously Untreated Mantle Cell Lymphoma
Keywords: Previously Untreated Mantle Cell Lymphoma |
|
| ON 01910.Na |
|
A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72 hour Continuous Intravenous Infusion Every Other Week In Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine
Keywords: Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine |
|
| Ab06002 |
|
A Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9mg/kg/day in Combination with Bortezomib and Dexamethasone to Placebo in Combination with Bortezomib and Dexamethasone in the Treatment of Patients with Relapsing Multiple Myeloma who Received One Previous therapy
Keywords: Relapsing Multiple Myeloma who Received One Previous therapy |
|
| CA204004 |
|
A Phase III, Randomized Open Label Trial of Lenalidomide/ Dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma
Keywords: Relapsed or Refractory Multiple Myeloma |
|
| Industry- Acute Myeloid Leukemia |
|
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Keywords: Newly Diagnosed Acute Myeloid Leukemia, Elderly Patients |